Data / Research funding / Pneumonia and Influenza
Pneumonia and Influenza: 754 NIH awards ($2B) to 212 organizations
754 NIH awards ($2B) in the NIH spending category Pneumonia and Influenza, to 212 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 754 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases: Mpox Clinical Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $150,331,625 | March 1, 2021 | February 28, 2026 | EWELL, MARIAN | reporter.nih.gov |
| NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE: AVIAN INFLUENZA RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $91,354,067 | April 1, 2021 | January 14, 2027 | WEBBY, RICHARD | reporter.nih.gov |
| COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $72,825,966 | September 10, 2019 | September 24, 2026 | KRAMMER, FLORIAN | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $62,580,113 | April 1, 2021 | September 17, 2026 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| CIVIC: University of Georgia Center for Influenza Vaccine Research in High Risk Populations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $53,879,677 | September 10, 2019 | September 9, 2026 | ROSS, TED | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $52,452,735 | September 10, 2019 | September 9, 2026 | MOODY, TONY | reporter.nih.gov |
| CEIRR: CORONAVIRUS RESEARCH ACTIVITIES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $50,650,417 | April 1, 2021 | September 29, 2026 | HENSLEY, SCOTT | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component B: Vaccine Manufacturing and Toxicology Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $44,296,051 | August 26, 2019 | March 13, 2028 | DENNY, THOMAS | reporter.nih.gov |
| Vanderbilt Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $36,564,580 | December 11, 2019 | November 30, 2026 | CREECH, CLARENCE BUDDY | reporter.nih.gov |
| DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $30,010,720 | May 2, 2019 | April 30, 2027 | WEBBY, RICHARD JOHN | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response (CEIRR): Avian Influenza Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $27,250,171 | April 1, 2021 | January 14, 2027 | LOWEN, ANICE | reporter.nih.gov |
| Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,789,202 | May 15, 2019 | April 30, 2027 | STAAT, MARY A | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $23,280,590 | August 1, 2021 | January 14, 2027 | PEKOSZ, ANDREW | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $22,981,366 | December 11, 2019 | November 30, 2026 | ROUPHAEL, NADINE GEORGES | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,625,203 | April 1, 2021 | September 14, 2027 | TOMPKINS, S. MARK | reporter.nih.gov |
| Vaccine and Treatment Evaluation Unit at Saint Louis University | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,219,564 | December 11, 2019 | November 30, 2026 | HOFT, DANIEL F. | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $19,720,676 | September 16, 2019 | September 15, 2026 | FRANKENFIELD, JILL | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,914,921 | September 16, 2019 | September 30, 2026 | BERES, WENDELL | reporter.nih.gov |
| Coordination for ARDS, Pneumonia, and Sepsis supporting Training, Organization and Network Efficiency (CAPSTONE) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $16,153,090 | May 1, 2023 | April 30, 2029 | SELF, WESLEY H | reporter.nih.gov |
| NIAID Influenza Data Processing and Communication Center: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,386,477 | April 1, 2021 | March 31, 2026 | BOUR, STEPHAN | reporter.nih.gov |
| University of Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,173,751 | December 11, 2019 | November 30, 2026 | WALD, ANNA | reporter.nih.gov |
| Kaiser Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,173,633 | December 11, 2019 | November 30, 2026 | JACKSON, LISA A | reporter.nih.gov |
| Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,340,237 | April 10, 2020 | November 30, 2026 | MULLIGAN, MARK JOSEPH | reporter.nih.gov |
| Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,580,221 | June 1, 2025 | May 31, 2027 | SETTE, ALESSANDRO | reporter.nih.gov |
| Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,115,898 | December 11, 2019 | November 30, 2026 | FRENCK, ROBERT WILSON | reporter.nih.gov |
| Development of an Optimized Adjuvanted TB Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,645,061 | September 30, 2021 | September 30, 2025 | EVANS, JAY | reporter.nih.gov |
| Advanced Development of a Universal Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,853,574 | September 9, 2019 | April 24, 2025 | LOCHER, CHRISTOPHER | reporter.nih.gov |
| ADJUVANT COMPARISON AND CHARACTERIZATION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $10,234,165 | September 1, 2022 | January 1, 2027 | FELGNER, PHILIP | reporter.nih.gov |
| Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,862,919 | March 22, 2022 | February 28, 2027 | FERNANDEZ-SESMA, ANA | reporter.nih.gov |
| Center for Modeling Complex Interactons | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $9,684,540 | March 15, 2015 | June 30, 2025 | WICHMAN, HOLLY A | reporter.nih.gov |
| A deep longitudinal analysis of next generation influenza vaccines in older adults | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $8,127,184 | January 1, 2022 | December 31, 2026 | UCAR, DUYGU | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers STATISTICAL, DATA MANAGEMENT AND COORDINATION CENTER (SDMCC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,400,390 | September 30, 2025 | September 29, 2026 | BOUR, STEPHAN | reporter.nih.gov |
| DEVELOPMENT OF VACCINES FOR INFLUENZA USING AN IMMUNO-MODULATOR ADJUVANT AND MULTI-PLATFORM APPROACH | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $7,281,050 | September 30, 2023 | September 29, 2028 | EL-KAMMASH, BRUXANNE | reporter.nih.gov |
| Adjuvant Development of the TLR4 Ligand BECC470s For Use in Influenza, S. aureus, and P. aeruginosa Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,143,498 | September 30, 2023 | September 29, 2028 | SORENSON, GREGORY | reporter.nih.gov |
| Emerging Infectious Diseases Research Center - East and Central Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,734,930 | June 1, 2020 | June 5, 2025 | NJENGA, M KARIUKI | reporter.nih.gov |
| Leveraging an ongoing longitudinal study of influenza vaccination to define immune signatures of response and risk of infection in older adults >75 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,605,926 | December 9, 2021 | November 30, 2026 | LENG, SEAN XIAO | reporter.nih.gov |
| DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,359,752 | September 30, 2023 | September 29, 2028 | LAPEK, JENNIFER | reporter.nih.gov |
| Developing Teixobactin for Respiratory Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,154,703 | March 22, 2021 | February 28, 2027 | HUGHES, DALLAS | reporter.nih.gov |
| DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,907,864 | September 30, 2023 | September 29, 2028 | BURKHART, DAVID | reporter.nih.gov |
| Discovery of adjuvants via novel modulation of innate immune pathways for vaccines against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,841,904 | September 30, 2019 | April 30, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| Drivers of individual variation in influenza vaccine response and protection from infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,827,282 | July 14, 2022 | June 30, 2027 | COBEY, SARAH | reporter.nih.gov |
| Task V02: Manufacture of Influenza for Human Challenge Clinical Trials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,587,695 | May 15, 2018 | May 31, 2026 | HASSEL, THOMAS | reporter.nih.gov |
| Advanced Development of Vaccines for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,495,941 | September 9, 2019 | May 31, 2027 | STAERZ, UWE | reporter.nih.gov |
| Development of vaccination strategies to elicit broadly protective immunity against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,165,779 | June 18, 2019 | June 30, 2029 | RAVETCH, JEFFREY VICTOR | reporter.nih.gov |
| Comparison of High vs. Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,116,475 | June 9, 2023 | March 31, 2028 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| The "Dynamics of the immune responses to repeat influenza vaccination exposures" (DRIVE) Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,955,723 | September 11, 2020 | June 30, 2026 | COBEY, SARAH | reporter.nih.gov |
| Structure based design of trimer interface epitope focused universal influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,864,362 | March 12, 2020 | February 28, 2025 | CROWE, JAMES E | reporter.nih.gov |
| Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,757,817 | November 22, 2021 | October 31, 2026 | MARASCO, WAYNE A. | reporter.nih.gov |
| DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,647,135 | June 29, 2020 | May 31, 2026 | ANTIA, RUSTOM NOSHIR | reporter.nih.gov |
| Tissue factor-dependent coagulation in thrombosis and immune responses | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,577,076 | February 1, 2021 | January 31, 2028 | MACKMAN, NIGEL | reporter.nih.gov |
| Molecular Analysis and Lineage Tracing of Influenza-Specific, Lung-Resident Memory B Cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,398,832 | April 7, 2020 | March 31, 2027 | RANDALL, TROY D | reporter.nih.gov |
| Inducible epithelial resistance: a program investigating mechanisms to protect against acute and chronic complications of pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,382,400 | March 5, 2019 | February 28, 2026 | EVANS, SCOTT E. | reporter.nih.gov |
| VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,300,145 | September 30, 2023 | September 29, 2026 | DOWLING, DAVID JAMES | reporter.nih.gov |
| Preclinical Pulmonary Fibrosis, an opportune rare disease cohort | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $4,290,758 | August 20, 2020 | July 31, 2026 | SCHWARTZ, DAVID ALBERT | reporter.nih.gov |
| Influenza pathogenesis in pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,248,239 | June 14, 2021 | May 31, 2027 | ADAMS WALDORF, KRISTINA M. | reporter.nih.gov |
| Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,220,934 | September 25, 2017 | August 31, 2027 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| Selecting HA glycosylation for improved vaccine responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,957,417 | June 9, 2021 | May 31, 2027 | ZAIA, JOSEPH | reporter.nih.gov |
| Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,950,305 | March 1, 2017 | July 31, 2025 | LIPKA, ELKE | reporter.nih.gov |
| Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,892,523 | August 20, 2021 | July 31, 2025 | AZOITEI, MIHAI LUCHIAN | reporter.nih.gov |
| Derivation and Validation of the Pediatric Community-Acquired Pneumonia Severity (PedCAPS) Score | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,862,565 | February 1, 2023 | January 31, 2028 | FLORIN, TODD ADAM | reporter.nih.gov |
| Cellular and molecular programming of lung resident T cell memory | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,857,630 | May 1, 2020 | April 30, 2027 | KOHLMEIER, JACOB E | reporter.nih.gov |
| Immune Dysfunction in HIV+ Opioid Users | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,823,539 | April 15, 2020 | January 31, 2027 | PAHWA, SAVITA | reporter.nih.gov |
| Genetic Investigation of Covid 19 in Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,774,284 | August 1, 2022 | July 31, 2027 | KAHN, MARK L | reporter.nih.gov |
| Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,749,095 | August 1, 2021 | May 31, 2027 | LUSTIGMAN, SARA | reporter.nih.gov |
| Heterosubtypic immunity to influenza virus mediated by MHC-E-restricted memory NK cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,727,019 | September 24, 2021 | August 31, 2027 | JOST, STEPHANIE | reporter.nih.gov |
| Discovery of Adjuvants that Direct T-cell Fates for Improved Safety and Efficacy in Vaccines Against Influenza and Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,714,524 | September 30, 2025 | September 29, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| Inborn errors of immunity in patients with life-threatening COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,707,765 | July 12, 2021 | June 30, 2026 | CASANOVA, JEAN-LAURENT | reporter.nih.gov |
| THE ROLE OF THE NON-CANONICAL INFLAMMASOME IN INNATE IMMUNITY | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,707,189 | June 11, 2021 | May 31, 2027 | AMER, AMAL O | reporter.nih.gov |
| Flipped Germinal Centers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,701,340 | September 17, 2021 | August 31, 2026 | WESEMANN, DUANE R. | reporter.nih.gov |
| Programming of PMN host-defense function during transendothelial migration | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,648,697 | June 11, 1993 | June 30, 2027 | KOMAROVA, YULIA A | reporter.nih.gov |
| CD4_T-cell_Immunity_in_the_Lung | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,557,478 | February 1, 2018 | January 31, 2025 | KOLLS, JAY K | reporter.nih.gov |
| Novel mechanisms regulating immunity to respiratory virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,546,288 | August 2, 2023 | July 31, 2027 | PAUST, SILKE | reporter.nih.gov |
| Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,518,508 | February 16, 2021 | January 31, 2027 | KOHUT, MARIAN L | reporter.nih.gov |
| Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,483,730 | September 1, 2023 | August 31, 2028 | ROSEN, DAVID A. | reporter.nih.gov |
| Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,479,164 | February 17, 2016 | April 30, 2027 | SURESH, MARULASIDDAPPA | reporter.nih.gov |
| Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,438,006 | April 23, 2021 | March 31, 2027 | TEYTON, LUC | reporter.nih.gov |
| Deciphering the relationship between structure, dynamics and function in helical bundle proteins | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,428,074 | May 1, 2017 | July 31, 2027 | DEGRADO, WILLIAM | reporter.nih.gov |
| Immunobiology of Influenza Virus-related Critical Illness in Young Hosts | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,406,427 | September 18, 2020 | August 31, 2025 | RANDOLPH, ADRIENNE G | reporter.nih.gov |
| Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,379,247 | August 1, 2019 | July 31, 2025 | GREENBERG, DAVID ELIHU | reporter.nih.gov |
| Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,375,497 | February 18, 2022 | January 31, 2027 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| Inhalation Therapy Platform for Coronavirus Infection Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,373,230 | September 17, 2021 | August 31, 2026 | STAYTON, PATRICK S. | reporter.nih.gov |
| Developing Inhibitors of Seasonal and Pandemic Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,352,410 | August 18, 2025 | July 31, 2029 | PLEMPER, RICHARD K. | reporter.nih.gov |
| A Phase III Randomized Controlled Trial of Azithromycin for RSV-induced Respiratory Failure in Children | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,324,945 | August 1, 2021 | July 31, 2027 | KONG, MICHELE | reporter.nih.gov |
| The role of Chlamydia pneumoniae infection in Alzheimer's Disease | NIH | National Institute on Aging | 2021 to 2025 | $3,300,943 | September 30, 2021 | June 30, 2027 | CROTHER, TIMOTHY ROBERT | reporter.nih.gov |
| Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,297,972 | April 2, 2021 | April 30, 2026 | RONG, LIJUN | reporter.nih.gov |
| Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,293,620 | September 1, 2020 | June 30, 2025 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| Hybrid Methods for Dynamic Structure Analysis of Proteins from Pathogenic Microorganisms | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,290,000 | July 1, 2021 | April 30, 2027 | MONTELIONE, GAETANO T | reporter.nih.gov |
| Programming Durable Immune Responses To Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,255,877 | December 18, 2018 | December 31, 2028 | ELLEBEDY, ALI HASSAN | reporter.nih.gov |
| Pulmonary pathophysiology sub-phenotypes of pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,223,607 | February 1, 2022 | January 31, 2027 | MIZGERD, JOSEPH P | reporter.nih.gov |
| Developing a bioprinted ventilated lung alveolar platform for investigating microbial interactions and influenza response | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,182,827 | August 19, 2025 | July 31, 2029 | OH, JULIA | reporter.nih.gov |
| Targeted Gene Delivery Systems Treating Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,172,072 | June 15, 2022 | May 31, 2026 | TIRRELL, MATTHEW | reporter.nih.gov |
| Development and optimization of a peptide inhibitor of influenza virus splicing for broad-spectrum antiviral therapy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,170,096 | August 1, 2025 | July 31, 2029 | TENOEVER, BENJAMIN R. | reporter.nih.gov |
| Development of peptide nucleic acid antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,164,488 | February 10, 2021 | January 31, 2025 | ARYA, DEV PRIYA | reporter.nih.gov |
| Structural interrogation of vaccine- and infection-induced B cell responses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,116,277 | February 22, 2022 | January 31, 2027 | BAJIC, GORAN | reporter.nih.gov |
| Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,114,564 | January 20, 2022 | December 31, 2026 | CHIRINOS MEDINA, JULIO ALONSO | reporter.nih.gov |
| Uncovering latent factors underlying weak and robust responses to influenza vaccine in healthy and obese older adults | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,095,170 | July 13, 2022 | June 30, 2027 | ALCORN, JOHN F | reporter.nih.gov |
| The role of cryptic influenza virus proteins in replication and pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,085,097 | July 9, 2025 | June 30, 2029 | MEHLE, ANDREW | reporter.nih.gov |
| Immunological characterization of rationally-designed vaccines against plague in mice and non-human primate models | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,082,735 | February 1, 2021 | July 31, 2026 | CHOPRA, ASHOK K | reporter.nih.gov |
| Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,081,358 | December 20, 2019 | November 30, 2025 | TSUJI, BRIAN | reporter.nih.gov |
| TCR-dependent and epigenetic mechanisms guiding influenza-specific CD4+ T cell responses in the lung | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,078,308 | August 1, 2025 | July 31, 2029 | HALE, JEFFREY SCOTT | reporter.nih.gov |
| Genetic Analysis of COVID-19 Susceptibility and Resistance Determinants in the Collaborative Cross | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,064,576 | September 25, 2020 | August 31, 2025 | HEISE, MARK T | reporter.nih.gov |
| Leveraging population-based human data to uncover mechanisms connecting Alzheimer's disease and common infections and facilitate vaccines repurposing for AD prevention | NIH | National Institute on Aging | 2021 to 2025 | $3,052,023 | September 30, 2021 | June 30, 2027 | OUKRAINTSEVA, SVETLANA V. | reporter.nih.gov |
| CoPARC: Colorado Pulmonary-Alcohol Research Collaborative | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $3,045,581 | August 1, 2011 | April 30, 2029 | BURNHAM, ELLEN L | reporter.nih.gov |
| Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,027,494 | July 1, 2023 | June 30, 2028 | NIZET, VICTOR | reporter.nih.gov |
| Clonal Dynamics of the antibody response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,017,736 | January 1, 2017 | December 31, 2026 | VICTORA, GABRIEL D | reporter.nih.gov |
| Evaluating darobactins as antimicrobial agents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,000,880 | April 1, 2021 | March 31, 2026 | LEWIS, KIM | reporter.nih.gov |
| Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,999,998 | June 7, 2023 | May 31, 2027 | COBURN, GLEN | reporter.nih.gov |
| Development of a Dual-Targeting ClpP Activating Antibiotic | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,999,619 | September 1, 2023 | August 31, 2026 | LAFLEUR, MICHAEL | reporter.nih.gov |
| Aminoglycosides with reduced ototoxicity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,999,400 | August 1, 2020 | February 28, 2026 | ARYA, DEV PRIYA | reporter.nih.gov |
| Universal Influenza A/B Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,998,889 | August 7, 2020 | April 30, 2026 | BAGLEY, KENNETH C | reporter.nih.gov |
| Vaccine Induced Immune-Inflammatory Response and Cardiovascular Risk | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,998,175 | April 1, 2021 | March 31, 2026 | CHENG, SUSAN | reporter.nih.gov |
| Innovations in Functional B Cell Epitope Discovery for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,991,588 | September 30, 2025 | September 29, 2026 | KELSOE, GARNETT | reporter.nih.gov |
| Prevention and Treatment of Pneumocystis Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,969,486 | May 21, 2020 | April 30, 2026 | NORRIS, KAREN A | reporter.nih.gov |
| Novel G protein-based RSV vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,967,937 | August 1, 2020 | March 31, 2027 | LI, SHENGQIANG | reporter.nih.gov |
| Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,964,030 | September 1, 2023 | August 31, 2026 | FRIZZELL, HANNAH | reporter.nih.gov |
| Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant ‘superbugs’ | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,944,400 | June 21, 2022 | May 31, 2027 | RAO, GAURI G | reporter.nih.gov |
| Kinase Regulation of Nuclear Speckle Function and Splicing during Influenza Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,940,532 | May 25, 2016 | August 31, 2026 | LYNCH, KRISTEN W | reporter.nih.gov |
| Targeting abnormal alveolar immune activation and failed epithelial repair in COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,933,325 | April 1, 2022 | March 31, 2026 | MISHARIN, ALEXANDER | reporter.nih.gov |
| REDES: a peer network and mobile health (mHealth) enhanced CHW model to maximize COVID-19 vaccination among low income Latinos | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $2,925,112 | April 13, 2022 | October 31, 2027 | PAGE, KATHLEEN R | reporter.nih.gov |
| Mechanistic evaluation of the role of circadian rhythms in acute lung injury and subsequent recovery | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,922,801 | September 20, 2021 | August 31, 2027 | SENGUPTA, SHAON | reporter.nih.gov |
| Accelerating viral outbreak detection in US cities using mechanistic models, machine learning and diverse geospatial data | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,917,739 | February 24, 2020 | January 31, 2025 | GALVANI, ALISON P | reporter.nih.gov |
| Rapid response to pandemic influenza via multi-antigen RNA-based vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,898,030 | February 10, 2022 | August 31, 2026 | CHAHAL, JASDAVE | reporter.nih.gov |
| Impact of repeated vaccination on the effectiveness of seasonal influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,895,020 | March 3, 2020 | February 28, 2027 | WAN, XIUFENG HENRY | reporter.nih.gov |
| Evolution and Transmission of Influenza Virus in Natural Human Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,893,554 | July 2, 2020 | June 30, 2026 | LAURING, ADAM | reporter.nih.gov |
| Dual drug delivery to lung/blood interface in respiratory infections. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,888,500 | April 20, 2021 | March 31, 2025 | MUZYKANTOV, VLADIMIR R | reporter.nih.gov |
| Development of an RSV vaccine for the elderly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,887,888 | March 2, 2020 | February 28, 2026 | MORRISON, TRUDY G. | reporter.nih.gov |
| Dissecting Yersinia Yop Targets in Neutrophils | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,883,504 | February 11, 2022 | January 31, 2027 | MECSAS, JOAN C | reporter.nih.gov |
| Community-based Design and Evaluation of a Conversational Agent to Promote SARS-COV2 Vaccination in Black Churches | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2024 | $2,872,823 | April 23, 2021 | April 1, 2025 | BICKMORE, TIMOTHY W. | reporter.nih.gov |
| Task B1C1: Vaccine and Treatment Evaluation Units (VTEU) Protocol Development and Implementation Natural History Challenge Study for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,862,138 | April 15, 2019 | November 30, 2024 | ORTIZ, JUSTIN | reporter.nih.gov |
| A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,858,436 | July 21, 2023 | June 30, 2027 | SEBAHAR, PAUL | reporter.nih.gov |
| Tfh dysfunction in HIV and Aging | NIH | National Institute on Aging | 2021 to 2024 | $2,856,124 | September 30, 2020 | April 30, 2026 | PAHWA, SAVITA | reporter.nih.gov |
| Virtual Patient Cohorts to Illuminate Immunologic Drivers of Influenza Severity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,844,812 | June 1, 2022 | May 31, 2027 | SMITH, AMBER M | reporter.nih.gov |
| Molecular Mechanisms and In Vivo Impact of Tethered Mucin 1-Influenza Virus Interactions | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,842,330 | January 15, 2021 | December 31, 2026 | SCULL, MARGARET ADELE | reporter.nih.gov |
| Betacoronaviruses: activation and antagonism of host innate immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,828,524 | May 24, 2018 | April 30, 2028 | WEISS, SUSAN R | reporter.nih.gov |
| Molecular Determinants of Usual Interstitial Pneumonia (UIP) | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,826,957 | April 1, 2022 | March 31, 2027 | SCHWARTZ, DAVID ALBERT | reporter.nih.gov |
| Protective functions of influenza-specific lung-resident memory B cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,821,316 | June 16, 2020 | May 31, 2027 | RANDALL, TROY D | reporter.nih.gov |
| Central role of Caspase-8 in control of host tolerance and resistance mechanisms in pulmonary macrophage populations during severe respiratory infections | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,808,365 | August 15, 2023 | May 31, 2027 | JAMIESON, AMANDA M | reporter.nih.gov |
| Mechanisms of regulatory T cell-mediated recovery from severe viral pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,783,450 | March 1, 2020 | June 30, 2029 | SINGER, BENJAMIN DAVID | reporter.nih.gov |
| Yersinia Outer-Membrane-Vesicle Vaccines Against Pneumonic Plague | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,776,243 | January 25, 2022 | December 31, 2026 | SUN, WEI | reporter.nih.gov |
| Child Lung Development Following a Cookstove Intervention: Evidence from GRAPHS | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,763,681 | July 1, 2017 | February 29, 2028 | JACK, DARBY | reporter.nih.gov |
| RNA:protein interactions that dictate the success of influenza virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,759,202 | February 2, 2022 | January 31, 2027 | MEHLE, ANDREW | reporter.nih.gov |
| Modeling the Coupled Dynamics of COVID-19 Transmission and Protective Behaviors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,758,288 | September 17, 2021 | August 31, 2027 | PARKER, ANDREW | reporter.nih.gov |
| Defining the Fc-correlates of protection against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,753,246 | March 11, 2020 | February 28, 2026 | LINGWOOD, DANIEL | reporter.nih.gov |
| Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,734,140 | July 11, 2022 | June 30, 2027 | RHODES, NATHANIEL JAMES | reporter.nih.gov |
| High-throughput assays and small-molecule discovery of antiviral candidates targeting influenza hemagglutinin | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,727,483 | May 1, 2021 | April 30, 2026 | WILSON, IAN A | reporter.nih.gov |
| Sensing living P. aeruginosa using D-alanine derived radiotracers | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,693,051 | May 1, 2021 | January 31, 2026 | WILSON, DAVID M | reporter.nih.gov |
| Innate immune signaling and stress response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,692,500 | March 15, 2016 | February 28, 2026 | KANNEGANTI, THIRUMALA-DEVI | reporter.nih.gov |
| Influenza Attenuates Innate Pulmonary Host Defense against Invasive Pulmonary Aspergillosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,690,414 | July 15, 2021 | June 30, 2027 | ROBINSON, KEVEN MARA | reporter.nih.gov |
| Syndecan-1 suppression of lung inflammation | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,688,430 | April 25, 2022 | March 31, 2026 | CHEN, PETER | reporter.nih.gov |
| Protein therapy to treat virus induced cardiopulmonary injury | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,684,754 | June 6, 2022 | May 31, 2026 | MA, JIANJIE | reporter.nih.gov |
| Nosocomial pneumonias impair cognitive function | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,684,149 | April 1, 2018 | August 31, 2027 | LIN, MIKE | reporter.nih.gov |
| Seasonal and universal Vaccination in aged populations with pre-existing immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,672,903 | May 21, 2021 | April 30, 2027 | KANG, SANG-MOO | reporter.nih.gov |
| Amyloid-mediated cognitive dysfunction in bacterial pneumonia after TBI | NIH | National Institute on Aging | 2025 | $2,663,195 | September 15, 2025 | August 31, 2029 | WAGENER, BRANT M | reporter.nih.gov |
| Targeting Pneumococcal Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,658,920 | February 1, 2020 | January 31, 2026 | WEISER, JEFFREY NEAL | reporter.nih.gov |
| Macrorecombination in isolated cell pairs via natural genetic transformation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,657,698 | May 21, 2021 | April 30, 2027 | EDDINGTON, DAVID | reporter.nih.gov |
| Genetically modified pigs to model NKT cell immunity to influenza virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,654,780 | April 6, 2022 | March 31, 2027 | DRIVER, JOHN | reporter.nih.gov |
| Monoclonal Antibody to Combat Pseudomonas Aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,646,807 | August 15, 2023 | July 31, 2028 | GOLDBERG, JOANNA B | reporter.nih.gov |
| The interface between L. pneumophila manipulation of host endoplasmic reticulum and innate immune subterfuge | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,645,600 | February 20, 2020 | January 31, 2026 | ISBERG, RALPH R. | reporter.nih.gov |
| Mechanisms of Pneumococcal Persistence During Carriage | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,644,208 | April 1, 1996 | June 30, 2029 | WEISER, JEFFREY NEAL | reporter.nih.gov |
| Quantifying Error Growth to Improve Infectious Disease Forecast Accuracy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,622,260 | June 9, 2021 | May 31, 2027 | SHAMAN, JEFFREY L | reporter.nih.gov |
| Balancing epithelial cell resistance and resilience to respiratory viral infections | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,621,215 | January 1, 2023 | December 31, 2027 | ORDOVAS-MONTANES, JOSE MANUEL | reporter.nih.gov |
| Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,617,783 | September 1, 2020 | December 31, 2025 | TRABBIC, KEVIN | reporter.nih.gov |
| Pandemrix and T Cell Immunology in Narcolepsy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,607,677 | May 13, 2021 | April 30, 2025 | MIGNOT, EMMANUEL J | reporter.nih.gov |
| GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,605,456 | June 1, 2023 | May 31, 2027 | HUTCHINS, JEFF T | reporter.nih.gov |
| A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,591,387 | July 15, 2022 | July 31, 2027 | HARDING, CHRISTIAN | reporter.nih.gov |
| ETS-family Transcription Factor Mediated Control of Pulmonary Inflammation Induced by Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,590,407 | February 1, 2019 | October 31, 2028 | HEATON, NICHOLAS S | reporter.nih.gov |
| Targeted genetic engineering of B cells to induce protective antibody responses to viral pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,577,835 | July 5, 2022 | June 30, 2027 | ADAIR, JENNIFER EILEEN | reporter.nih.gov |
| Innate immune-mediated control of pulmonary Legionella pneumophila infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,572,725 | November 16, 2015 | June 30, 2027 | SHIN, SUNNY | reporter.nih.gov |
| Rapid, Breath Volatile Metabolite-Based Diagnosis, Species Identification, and Antibiotic Resistance Profiling in Bacterial Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,571,160 | February 15, 2023 | January 31, 2028 | KOO, SOPHIA | reporter.nih.gov |
| Rapid Manufacturing of a Universal Flu Vaccine Using TMV-conjugated Centralized Antigens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,568,474 | June 1, 2020 | May 31, 2026 | WEAVER, ERIC A | reporter.nih.gov |
| VACCINE ADJUVANT DISCOVERY PROGRAM (VADP) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,547,484 | September 30, 2025 | September 29, 2026 | LEVY, OFER | reporter.nih.gov |
| Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,541,116 | September 19, 2022 | July 31, 2027 | LAI, SAMUEL | reporter.nih.gov |
| Engineering Protein Antigens and their Presentation from Multivalent Scaffolds | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,480,883 | July 7, 2023 | June 30, 2028 | KANE, RAVI S. | reporter.nih.gov |
| Deciphering the Heterogeneous Response to Influenza by a Multi-Scale Systems Approach | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,480,693 | July 14, 2022 | June 30, 2027 | FORST, CHRISTIAN | reporter.nih.gov |
| Lung leukocytes promote alveolar epithelial regeneration after severe injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,469,157 | May 1, 2020 | April 30, 2026 | ARPAIA, NICHOLAS | reporter.nih.gov |
| Treatment of Inflammatory Complications of Respiratory Infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,463,597 | June 20, 2022 | July 31, 2026 | LARK, MICHAEL WILLIAM | reporter.nih.gov |
| New mouse model to better predict human immunity to influenza vaccination and infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,461,120 | August 1, 2021 | July 31, 2025 | MASOPUST, DAVID | reporter.nih.gov |
| Modeling the development, structure and regulation of T cell memory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,452,681 | March 1, 2011 | August 31, 2026 | YATES, ANDREW | reporter.nih.gov |
| Dynamic regulatory network models of human response to influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,434,869 | August 17, 2020 | May 31, 2026 | MARAZZI, IVAN | reporter.nih.gov |
| Functional and genetic constraints on influenza virus replication and fidelity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,431,062 | June 17, 2022 | May 31, 2027 | LAURING, ADAM | reporter.nih.gov |
| hHv1 channels in neutrophils and the innate immune inflammatory response | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,426,520 | August 5, 2022 | June 30, 2027 | GOLDSTEIN, STEVE A N | reporter.nih.gov |
| Targeting Estrogenic pathways in Tregs to promote ARDS resolution | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,413,250 | June 1, 2022 | May 31, 2026 | D'ALESSIO, FRANCO RAFAEL | reporter.nih.gov |
| Let-7b in Extracellular Vesicles Secreted by Bronchial Epithelial Cells Increases the Antibiotic Sensitivity of Pseudomonas | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,409,204 | December 15, 2020 | November 30, 2025 | STANTON, BRUCE A. | reporter.nih.gov |
| Predictive fitness models for influenza vaccine strain selection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,404,863 | January 13, 2022 | August 10, 2025 | LUKSZA, MARTA | reporter.nih.gov |
| Structure and dynamics of RNA elements regulating viral aberrant RNA synthesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,396,295 | September 8, 2022 | August 31, 2027 | TE VELTHUIS, AREND JAN | reporter.nih.gov |
| SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,380,033 | March 4, 2021 | February 28, 2026 | CONE, RICHARD | reporter.nih.gov |
| Using three-dimensional protein networks to uncover immuno-modulatory molecular phenotypes in infectious disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,378,125 | August 1, 2021 | July 31, 2027 | DAS, JISHNU | reporter.nih.gov |
| Fungal dysbiosis regulation of post-influenza bacterial pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,376,545 | July 16, 2021 | June 30, 2025 | CHEN, PETER | reporter.nih.gov |
| Improve Lung Regeneration Through Targeting Tuft Cells Following Viral Infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,371,262 | August 20, 2021 | June 30, 2026 | QUE, JIANWEN | reporter.nih.gov |
| Defining the Interplay Between Viral Adaptation and Host Proteostasis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,362,578 | September 19, 2022 | July 31, 2027 | SHOULDERS, MATTHEW DONALD | reporter.nih.gov |
| A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,345,744 | December 27, 2022 | November 30, 2027 | PICKING, WENDY L. | reporter.nih.gov |
| Anticipating and rapidly responding to respiratory virus outbreaks with continuous air sampling in K-12 schools | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,338,302 | January 18, 2023 | December 31, 2027 | O'CONNOR, DAVID H. | reporter.nih.gov |
| Mechanisms of innate resistance to virus infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,323,545 | February 1, 2017 | January 31, 2027 | YOUNT, JACOB | reporter.nih.gov |
| Cardiac microlesion formation during invasive pneumococcal disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,308,740 | November 1, 2014 | May 31, 2030 | ORIHUELA, CARLOS J | reporter.nih.gov |
| Follistatin-like 1 Mediated Host Defense in Bacterial Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,305,697 | July 1, 2022 | June 30, 2027 | CAMPFIELD, BRIAN T | reporter.nih.gov |
| IL-33 induced-lL-9 producing type 2 innate lymphoid cells in the regulation of acute lung injury after hematopoietic stem cell transplantation (HSCT) in pediatric patients | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,303,969 | January 1, 2022 | June 30, 2026 | PACZESNY, SOPHIE | reporter.nih.gov |
| Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or acute respiratory distress syndrome patients receiving different modes of ventilation support | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,301,184 | July 1, 2023 | June 30, 2027 | LONGEST, P. WORTH | reporter.nih.gov |
| Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,299,720 | August 16, 2024 | January 31, 2027 | LIPKA, ELKE | reporter.nih.gov |
| Deciphering the role of peroxisomes in bacterial pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,298,625 | September 19, 2022 | July 31, 2027 | O'CONNOR, TAMARA | reporter.nih.gov |
| Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,298,010 | April 25, 2022 | May 30, 2026 | COOPER, COLLEEN DOYLE | reporter.nih.gov |
| Identifying Influenza Virus Infection Severity and Outcome Signatures Through Artificial Intelligence-driven Analyses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,286,566 | July 7, 2022 | June 30, 2028 | DUPONT, CHRISTOPHER L. | reporter.nih.gov |
| Prevalence effects in visual search: Theoretical and practical implications | NIH | National Eye Institute | 2021 to 2025 | $2,283,459 | April 1, 2007 | June 30, 2029 | WOLFE, JEREMY M | reporter.nih.gov |
| Biology of Lymphangiogenesis in the Adult Lung | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,281,864 | July 1, 2022 | June 30, 2027 | JONES, MATTHEW ROBERT | reporter.nih.gov |
| Protection and Immunity after Polyanhydride Nanoparticle Vaccination against Avian Influenza A Virus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,280,238 | November 14, 2022 | October 31, 2027 | LEGGE, KEVIN L | reporter.nih.gov |
| Roles of tissue-resident helper T cells in mucosal immunity against influenzainfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,276,812 | February 1, 2022 | April 30, 2025 | SUN, JIE | reporter.nih.gov |
| LOX-1 as a protective countermeasure in response to lung infection | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,274,599 | June 15, 2023 | May 31, 2027 | QUINTON, LEE | reporter.nih.gov |
| Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,261,035 | January 15, 2020 | December 31, 2025 | AINSLIE, KRISTY M | reporter.nih.gov |
| Bioactivities of pneumococcal cell wall in neuropathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,255,100 | November 4, 2016 | January 31, 2027 | TUOMANEN, ELAINE I | reporter.nih.gov |
| Elucidating the roles of alveolar macrophage inflammation and self renewal during influenza infection | NIH | National Institute on Aging | 2021 to 2025 | $2,252,254 | August 15, 2020 | April 30, 2030 | SUN, JIE | reporter.nih.gov |
| Role of spatial structure in shaping viral population diversity and evolution | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,238,488 | August 17, 2020 | July 31, 2025 | LOWEN, ANICE C | reporter.nih.gov |
| Mechanistic modeling of the innate immune responses of the human lung to understand the inter-individual heterogeneity of COVID-19 pneumonia | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,227,734 | July 1, 2023 | June 30, 2027 | MEHRAD, BORNA | reporter.nih.gov |
| Functional Implications of Tfh Cell Heterogeneity after Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,219,856 | January 24, 2022 | December 31, 2026 | RANDALL, TROY D | reporter.nih.gov |
| The role of ACE2 in Influenza viral infection mediated immune compromise and subsequent bacterial lung infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,219,353 | May 15, 2020 | April 30, 2026 | JIA, HONGPENG | reporter.nih.gov |
| Interplay between influenza virus and S1P-metabolizing enzymes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,218,924 | June 10, 2021 | May 31, 2027 | HAHM, BUMSUK | reporter.nih.gov |
| Regulation of the interferon lamda receptor by influenza | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,215,117 | April 1, 2006 | June 30, 2026 | MALLAMPALLI, RAMA K | reporter.nih.gov |
| Development of vaccine approaches to elicit broadly protective influenza-specific immune responses in infants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,208,932 | August 5, 2020 | July 31, 2026 | ALEXANDER-MILLER, MARTHA ANN | reporter.nih.gov |
| Loss of Endothelial S1PR1 Drives Post-Influenza Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,206,371 | June 15, 2023 | May 31, 2028 | KNIPE, RACHEL S | reporter.nih.gov |
| Identification and characterization of effector memory B cell populations that dominate memory responses to subsequent influenza infection and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,206,266 | August 3, 2020 | July 31, 2025 | LUND, FRANCES E. | reporter.nih.gov |
| Coordinated regeneration of lung epithelial and endothelial compartments | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,201,693 | August 20, 2022 | July 31, 2026 | VAUGHAN, ANDREW | reporter.nih.gov |
| Control of influenza virus induced type I interferon signaling during pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,200,686 | November 1, 2022 | October 31, 2027 | HEATON, NICHOLAS S | reporter.nih.gov |
| Forecasting influenza evolution on a heterogeneous immune landscape | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,197,907 | February 15, 2022 | January 31, 2028 | BEDFORD, TREVOR BC | reporter.nih.gov |
| Novel mechanisms of Alveolar Macrophage-Dependent Antifungal Innate Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,192,702 | January 8, 2020 | December 31, 2025 | WRIGHT, TERRY W | reporter.nih.gov |
| Impact of inflammatory lipids on Yersinia pestis infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,171,406 | July 14, 2023 | June 30, 2027 | LAWRENZ, MATTHEW B | reporter.nih.gov |
| Automated chemo-enzymatic synthesis of N-glycans for host-pathogen interactions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,169,230 | June 1, 2022 | May 31, 2027 | BOONS, GEERT-JAN | reporter.nih.gov |
| Developmental Exposures to Arsenic: Pneumonia, Immunity, and Microbiomes (DEAPIM) | NIH | National Institute of Environmental Health Sciences | 2023 to 2025 | $2,157,462 | February 5, 2022 | December 31, 2026 | PARVEZ, MUHAMMAD F | reporter.nih.gov |
| Effective Primary care practices that Enhance Recovery Trajectories after pneumonia (EXPERT) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,148,392 | September 15, 2023 | June 30, 2028 | IWASHYNA, THEODORE J | reporter.nih.gov |
| Genetic Contributors to the Impact of Sex on Heterogeneity in Flu Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,125,850 | July 11, 2022 | June 30, 2027 | KO, DENNIS CHUN-YONE | reporter.nih.gov |
| Linking SARS-CoV-2 Aerosol Viability and Environmental Factors in Healthcare Settings | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,121,919 | August 17, 2023 | July 31, 2027 | KELLY, KERRY | reporter.nih.gov |
| Influenza & COVID Obstetric and Perinatal Epidemiology Study in India | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,121,321 | September 23, 2022 | August 31, 2027 | HIBBERD, PATRICIA L | reporter.nih.gov |
| THE IMPACT OF ADVANCED AGE AND SEX ON HUMORAL IMMUNITY TO STREPTOCOCCUS PNEUMONIAE | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,121,108 | September 1, 2022 | August 31, 2027 | HAAS, KAREN M | reporter.nih.gov |
| mRNA-encoded Cas13 as a pan-respiratory antiviral | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,120,971 | January 23, 2023 | December 31, 2027 | SANTANGELO, PHILIP J | reporter.nih.gov |
| Structure and Function of Legionella pneumophila Lysine Methyltransferases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,118,862 | March 21, 2022 | February 28, 2027 | TRIEVEL, RAYMOND C | reporter.nih.gov |
| Macrophage-targeting Nanoplatforms as Immunotherapy against Pulmonary Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,117,352 | July 1, 2017 | November 30, 2028 | SAILOR, MICHAEL J | reporter.nih.gov |
| TRPV4 Regulates Mechanosensitive Macrophage Functions in Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,097,481 | February 1, 2021 | January 31, 2027 | SCHERAGA, RACHEL GREENBERG | reporter.nih.gov |
| Interleukin-27 in host response to Legionella infection | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,096,982 | July 1, 2023 | June 30, 2027 | BOSMANN, MARKUS | reporter.nih.gov |
| Alveolar responses to viral lung infection | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,088,426 | June 20, 2022 | May 31, 2027 | HOOK, JAIME LYNN | reporter.nih.gov |
| IDENTIFICATION AND CHARACTERIZATION OF T CELL EPITOPES FROM BACTERIAL PATHOGENS CAUSING PNEUMONIA | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,079,792 | September 30, 2025 | September 29, 2026 | PETERS, BJOERN | reporter.nih.gov |
| Biophysical studies of viral membrane fusion proteins | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,067,810 | July 1, 2022 | June 30, 2027 | MUNRO, JAMES B | reporter.nih.gov |
| Transcriptional Regulation of Migrating Neutrophils during Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,062,500 | July 1, 2021 | June 30, 2027 | TRABER, KATRINA | reporter.nih.gov |
| Integrating measurements of immune escape and in vitro replication with computational models to understand and predict the antigenic evolution of seasonal A/H3N2 influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,056,935 | February 7, 2022 | January 31, 2027 | SMITH, DEREK JAMES | reporter.nih.gov |
| Regulation of the host immune response to influenza by the checkpoint receptor Tim3 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,054,835 | May 1, 2020 | April 30, 2026 | CHO, JOSALYN L | reporter.nih.gov |
| Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,049,871 | June 21, 2024 | May 31, 2027 | SCOTT, DAVID W | reporter.nih.gov |
| IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,049,821 | May 15, 2024 | April 30, 2027 | HUTCHINS, JEFF T | reporter.nih.gov |
| Influenza A Inhibits TH17 Host Defense Against Bacterial Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,049,603 | January 1, 2012 | March 31, 2026 | ALCORN, JOHN F | reporter.nih.gov |
| Biophysical constraints of influenza neuraminidase evolution | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,049,096 | June 28, 2022 | May 31, 2027 | WU, NICHOLAS C. | reporter.nih.gov |
| Sequence-function relationship of influenza broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,039,386 | January 25, 2022 | December 31, 2026 | WU, NICHOLAS C. | reporter.nih.gov |
| Cellular and molecular mechanisms of alveolar repair | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,019,414 | August 1, 2023 | May 31, 2027 | DESAI, TUSHAR JASUBHAI | reporter.nih.gov |
| Adjuvant Development of the TLR4 Ligand BECC470s For Use in Influenza, S. aureus, and P. aeruginosa Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,018,199 | September 30, 2023 | September 29, 2026 | SORENSON, GREGORY | reporter.nih.gov |
| Consequences of Direct Viral-Bacterial Interactions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,014,549 | January 5, 2022 | December 31, 2026 | ROSCH, JASON W. | reporter.nih.gov |
| An immunodominance-based Pan-Pneumovirus vaccine for protection against RSV and hMPV | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,007,500 | June 6, 2023 | May 31, 2028 | MOUSA, JARROD | reporter.nih.gov |
| Pneumocystis: Macrophage & Epithelial Activation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,005,500 | July 10, 1993 | January 31, 2027 | LIMPER, ANDREW H | reporter.nih.gov |
| Early Responses to Influenza A Virus Replication In Vivo | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,004,034 | March 1, 2020 | February 28, 2026 | LANGLOIS, RYAN | reporter.nih.gov |
| A new class of antibiotic to address Antimicrobial Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,999,995 | May 1, 2024 | April 30, 2027 | TESTA, CHARLES | reporter.nih.gov |
| Megakaryocyte regulation by the gut microbiome | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,980,652 | June 1, 2023 | March 31, 2027 | ZENG, MELODY Y | reporter.nih.gov |
| Lung Macrophage Memory Development and Responses in Secondary Pneumonia and Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,972,366 | August 27, 2021 | July 31, 2026 | MISHRA, BIBHUTI BHUSAN | reporter.nih.gov |
| The role of neutrophils in the age-driven decline in anti-pneumococcal vaccine responses | NIH | National Institute on Aging | 2021 to 2025 | $1,966,375 | September 30, 2021 | May 31, 2027 | BOU GHANEM, ELSA | reporter.nih.gov |
| Mechanism of Protein Synthesis and Translational Control | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,962,066 | June 1, 2021 | May 31, 2027 | JOSEPH, SIMPSON | reporter.nih.gov |
| Molecular regulation of protective CD8 immunity against influenza infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,956,077 | February 10, 2015 | April 30, 2025 | SUN, JIE | reporter.nih.gov |
| Combining innovative molecular adjuvanting approaches with novel adenoviral vector delivery to generate a universal influenza vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,952,609 | July 1, 2022 | June 30, 2027 | COUGHLAN, LYNDA | reporter.nih.gov |
| Tissue niches for ILC3 development in newborn's lung | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,949,066 | January 1, 2021 | March 14, 2025 | DESHMUKH, HITESH | reporter.nih.gov |
| Unraveling the Viral Infection Pathway with Virus-locked Observation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,947,117 | August 15, 2017 | May 31, 2027 | WELSHER, KEVIN | reporter.nih.gov |
| Role of preexisting immunity on airborne transmission of influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,945,314 | February 1, 2023 | January 31, 2027 | LAKDAWALA, SEEMA S. | reporter.nih.gov |
| Microbiota Regulation of Pulmonary Complications Post-HCT | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,941,600 | September 20, 2021 | August 31, 2026 | ZHOU, XIAOFENG | reporter.nih.gov |
| Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,932,841 | February 1, 2016 | October 31, 2026 | KOLLS, JAY K | reporter.nih.gov |
| Impact of Aging on Oxysterol Regulation of Alveolar Macrophage Function during S. pneumoniae | NIH | National Institute on Aging | 2023 to 2025 | $1,932,027 | September 1, 2023 | May 31, 2028 | STOUT DELGADO, HEATHER WINONA | reporter.nih.gov |
| Molecular mechanisms underlying organ penetration in disseminated pneumococcal infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,924,214 | November 1, 2022 | October 31, 2027 | ORIHUELA, CARLOS J | reporter.nih.gov |
| Skin vaccination and generation of protective lung-tropic memory T cells | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,906,147 | December 18, 2023 | October 31, 2028 | KUPPER, THOMAS S. | reporter.nih.gov |
| Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,900,000 | September 22, 2021 | August 31, 2027 | STRUTT, TARA MARLENE | reporter.nih.gov |
| Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,899,426 | June 1, 2024 | May 31, 2027 | KUTSCHER, HILLIARD | reporter.nih.gov |
| Functional diversity of lung pericytes in lung injury | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,899,368 | December 15, 2022 | November 30, 2027 | HUNG, CHI F | reporter.nih.gov |
| Elucidating the role of type I interferon signaling and macrophage-derived inflammation in the juvenile host with viral pneumonia | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,898,753 | May 8, 2023 | February 28, 2027 | COATES, BRIA M | reporter.nih.gov |
| Control of antiviral memory CD8+ T cell longevity by extracellular ATP sensing | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,894,856 | July 1, 2022 | June 30, 2027 | BORGES DA SILVA, HENRIQUE | reporter.nih.gov |
| Harnessing type I interferon to promote lung-resident memory CD4 T cell immunity against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,893,259 | June 21, 2022 | May 31, 2027 | MCKINSTRY, KARL KAI | reporter.nih.gov |
| Investigating protective adaptive immune responses to influenza antigens using human tonsil organoids | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,890,792 | June 1, 2023 | May 31, 2028 | WAGAR, LISA | reporter.nih.gov |
| A new mucosal adjuvant for augmenting influenza vaccines in elderly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,887,393 | May 24, 2021 | April 30, 2027 | WU, MEI X | reporter.nih.gov |
| Real-time tracking of virus evolution for vaccine strain selection and epidemiological investigation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,886,759 | August 23, 2016 | May 31, 2026 | BEDFORD, TREVOR BC | reporter.nih.gov |
| 7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,881,701 | April 26, 2023 | March 31, 2026 | MARATHI, UPENDRA | reporter.nih.gov |
| Markers and regulation of regulatory CD8+ T cells during influenza-induced lung immunopathology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,878,277 | July 1, 2021 | June 30, 2027 | HUANG, WEISHAN | reporter.nih.gov |
| Innate NLRC4 signaling controls adaptive immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,874,689 | June 20, 2023 | May 31, 2028 | SUTTERWALA, FAYYAZ S. | reporter.nih.gov |
| Colistin resistance in extensively drug-resistant Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,869,812 | March 15, 2014 | March 31, 2025 | DOI, YOHEI | reporter.nih.gov |
| Context dependent amino acid availability and sensing determines humoral immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,869,187 | February 10, 2022 | January 31, 2027 | ZENG, HU | reporter.nih.gov |
| Understanding and targeting fibroblast activation in influenza-triggered lung inflammation and post-viral disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,866,950 | September 1, 2023 | August 31, 2028 | BOYD, DAVID FIELDING | reporter.nih.gov |
| Targeting Influenza A Virus by a Carbohydrate-inspired Strategy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,866,200 | September 18, 2019 | December 31, 2027 | WONG, CHI-HUEY | reporter.nih.gov |
| Common Post-Infectious Premature Epigenetic Aging | NIH | National Institute on Aging | 2023 to 2025 | $1,844,091 | August 15, 2023 | April 30, 2028 | DINARDO, ANDREW R | reporter.nih.gov |
| Memory CD8 T cell localization and protection from influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,841,052 | November 1, 2014 | December 31, 2024 | HARTY, JOHN T | reporter.nih.gov |
| Siderophore based molecular imaging of pulmonary infections | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,833,928 | July 1, 2023 | June 30, 2028 | KOTAGIRI, NALINIKANTH | reporter.nih.gov |
| Antibiotic tolerance: membraneless organelles and autolysin regulation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,820,000 | May 5, 2022 | April 30, 2027 | TUOMANEN, ELAINE I | reporter.nih.gov |
| Addressing Vaccine AcceptaNce in Carceral Settings through Community Engagement (ADVANCE) | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2024 | $1,811,735 | September 26, 2022 | December 31, 2026 | PUGLISI, LISA BALZANO | reporter.nih.gov |
| Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,799,789 | May 1, 2024 | April 30, 2027 | PARHI, AJIT K | reporter.nih.gov |
| Virulence Factor at the Interface of Viral and Cellular mRNA Nuclear Export | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,776,477 | May 6, 2020 | April 30, 2026 | FONTOURA, BEATRIZ MA | reporter.nih.gov |
| Endolysins as tools to eradicate pneumococcal biofilms and development ofprotective immunity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,770,586 | December 9, 2022 | November 30, 2027 | GONZALEZ-JUARBE, NORBERTO | reporter.nih.gov |
| Molecular Mechanisms Regulating Bacterial Two-component Signaling Systems | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,766,612 | February 8, 2023 | January 31, 2028 | FUENTES, ERNESTO JORGE | reporter.nih.gov |
| Regulation Of Lung Immunity By Antibody Glycosylation | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,761,927 | February 13, 2024 | December 31, 2028 | WANG, TAIA | reporter.nih.gov |
| Adrenergic control of circadian rhythms in CD8 T cells responding to influenza | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,731,396 | July 1, 2023 | June 30, 2028 | FARRAR, JOHN DAVID | reporter.nih.gov |
| Leveraging community-based behavioral health to increase vaccine uptake in Latinx adults with mental illness | NIH | National Institute of Nursing Research | 2022 to 2024 | $1,714,097 | September 26, 2022 | March 10, 2025 | DAVISON, KIRSTEN | reporter.nih.gov |
| Vaccination responses in lung transplant recipients | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,708,641 | August 5, 2022 | July 31, 2027 | NICOLLS, MARK ROBERT | reporter.nih.gov |
| Mechanism and targeting of inflammasome activation in lung inflammation and injury | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,696,153 | February 16, 2023 | January 31, 2028 | LIU, GANG | reporter.nih.gov |
| A Flexible High-Throughput Immunological Assay to Support Next-Generation Influenza Vaccine Studies | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,679,190 | May 3, 2023 | April 30, 2026 | SIGAL, GEORGE B | reporter.nih.gov |
| Legionella effectors reveal novel signaling function for the ribosome quality control (RQC) pathway | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,677,236 | June 15, 2016 | May 31, 2025 | MUKHERJEE, SHAERI | reporter.nih.gov |
| Mechanisms of platelet reprogramming during influenza infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,675,000 | July 1, 2020 | June 30, 2025 | KOUPENOVA, MILKA | reporter.nih.gov |
| A redox-sensitive switch in the macrophage nucleus regulates acute phase inflammatory injury | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,671,361 | June 1, 2022 | May 31, 2026 | BONINI, MARCELO G. | reporter.nih.gov |
| Text4Vax: Understanding the Implementation of Informational Text Messages for Pediatric Influenza Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,667,321 | April 15, 2024 | February 29, 2028 | STOCKWELL, MELISSA S | reporter.nih.gov |
| Use of Clinical Samples to Identify Influenza Virus Antigenic Variants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,659,372 | July 17, 2019 | June 30, 2025 | WAN, XIUFENG HENRY | reporter.nih.gov |
| PspA binds necroptotic cells to cause disease and transmit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,641,325 | September 24, 2020 | August 31, 2025 | ORIHUELA, CARLOS J | reporter.nih.gov |
| Impact of nucleotide metabolism on bacterial clearance | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,637,144 | August 15, 2022 | July 31, 2027 | RIQUELME COLET, SEBASTIAN ALEJANDRO | reporter.nih.gov |
| BE IMMUNE: Behavioral Economics to Improve and Motivate vaccination Using Nudges through the EHR | NIH | National Institute on Aging | 2022 to 2024 | $1,628,541 | August 15, 2020 | August 31, 2025 | MEHTA, SHIVAN JATIN | reporter.nih.gov |
| A Phase II Study Evaluating the Safety and Efficacy of Whole-Cell Pneumococcal Vaccine (wSp) in Reducing Nasopharyngeal Colonization by Streptococcus pneumoniae in Young Children | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,616,462 | March 15, 2024 | February 29, 2028 | PICHICHERO, MICHAEL E | reporter.nih.gov |
| Understanding alterations to mucus composition and function in asthma | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,614,918 | July 1, 2022 | April 30, 2027 | DUNCAN, GREGG | reporter.nih.gov |
| Immunogenetics of COVID-19 Immune Response | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,614,396 | August 1, 2024 | July 31, 2029 | KENNEDY, RICHARD B | reporter.nih.gov |
| Liposomal Encapsulation Vaccine Design for Pneumococcal Disease in Aged Subjects | NIH | National Institute on Aging | 2022 to 2025 | $1,602,868 | August 4, 2022 | April 30, 2027 | PFEIFER, BLAINE A. | reporter.nih.gov |
| Inflammatory mechanisms responsible for the development of multiple organ dysfunction in pediatric patients following allogeneic blood and marrow transplantation (BMT). | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $1,598,857 | February 1, 2020 | January 31, 2026 | COOKE, KENNETH R | reporter.nih.gov |
| Solitary chemosensory / tuft cells in lung regeneration and inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,597,401 | June 1, 2020 | May 31, 2025 | VAUGHAN, ANDREW | reporter.nih.gov |
| Novel Biamyxins targeting multidrug resistant Gram-negative bacterial infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,596,741 | July 2, 2024 | June 30, 2029 | ZHAO, YANAN | reporter.nih.gov |
| The Role of Eicosanoid-PPAR axis in Exacerbating Post-Influenza Staphylococcus aureus Super-infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,594,729 | January 21, 2022 | December 31, 2026 | TAM, VINCENT | reporter.nih.gov |
| DC-subset-tailored vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,560,000 | June 17, 2020 | May 31, 2026 | IGYARTO, BOTOND Z | reporter.nih.gov |
| Immune mechanisms of influenzaâÂÂinduced exacerbation of atherosclerosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,558,220 | August 15, 2020 | July 31, 2025 | GOPAL, RADHA | reporter.nih.gov |
| Acquired CFTR Dysfunction in Alcohol-related Lung Pathology | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $1,544,404 | January 1, 2020 | December 31, 2024 | RAJU, S.VAMSEE | reporter.nih.gov |
| Impact of intra-host population structure on influenza virus antigenic evolution | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,543,925 | December 9, 2021 | November 30, 2026 | LOWEN, ANICE C | reporter.nih.gov |
| Investigation of host glycan requirements for the transmission of influenza viruses at the human-animal interface | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,541,846 | July 26, 2024 | June 30, 2029 | MANICASSAMY, BALAJI | reporter.nih.gov |
| Broad spectrum protection and immune responses induced by an NP-based universal influenza vaccine in heterologous NHP challenge model | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,540,227 | September 26, 2023 | August 31, 2026 | NICOLAS, FLORENCE | reporter.nih.gov |
| Novel role for protein kinase D in airway inflammation and antiviral immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,540,000 | March 13, 2020 | February 28, 2026 | GEORAS, STEVE N | reporter.nih.gov |
| Acidosis in pulmonary endothelial injury and repair | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,540,000 | February 1, 2022 | January 31, 2027 | LEE, JI YOUNG | reporter.nih.gov |
| Understanding evasion of cell intrinsic innate immunity in viral populations with high rates of replicative failure | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,535,710 | August 1, 2022 | May 31, 2027 | RUSSELL, ALISTAIR B | reporter.nih.gov |
| 1/2 WIN Ratio Analysis to Determine a Strategy of Non-Invasive SUpport for Respiratory Failure in the EmeRgency Department (WINDSURFER) | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,535,439 | September 15, 2025 | December 31, 2026 | WANG, HENRY E. | reporter.nih.gov |
| Defective Zn Homeostasis impairs host defense against pneumococcal pneumonia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,534,270 | December 22, 2021 | November 30, 2026 | KNOELL, DAREN LEE | reporter.nih.gov |
| Fibrin in the Infected Lung | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,530,164 | February 15, 2024 | January 31, 2028 | MIZGERD, JOSEPH P | reporter.nih.gov |
| A NOVEL STRATEGY TO INHIBIT SARS-COV-2 INFECTION AND COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,525,325 | June 13, 2024 | April 30, 2029 | GALLAY, PHILIPPE ANDRE | reporter.nih.gov |
| Serological Biomarkers for Coccidioidomycosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,518,970 | June 7, 2021 | May 31, 2026 | MAGEE, D MITCHELL | reporter.nih.gov |
| Uncovering and understanding the many functions of ICAM-1 in the lungs during homeostasis and innate immune responses | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,518,050 | August 26, 2024 | May 31, 2028 | DOERSCHUK, CLAIRE M | reporter.nih.gov |
| Dual oxidase and lactoperoxidase in influenza infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,510,000 | February 19, 2020 | January 31, 2025 | RADA, BALAZS | reporter.nih.gov |
| E3 Ligase-Mediated Immunosuppression in Acute Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,507,608 | February 1, 2010 | June 30, 2026 | MALLAMPALLI, RAMA K | reporter.nih.gov |
| Predictive Modeling of Estradiol Effects and Sex Differences on Immunopathology during Influenza Infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,502,325 | June 18, 2024 | May 31, 2029 | SHOEMAKER, JASON EDWARD | reporter.nih.gov |
| Metal-binding Isosteres for Influenza Endonuclease Inhibitors and Beyond | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,482,645 | April 1, 2020 | March 31, 2026 | COHEN, SETH M | reporter.nih.gov |
| Novel coenzyme Q6 variant reveals non-immune determinants of survival during pneumococcal sepsis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,481,057 | August 26, 2024 | July 31, 2028 | MORLEY, SHARON CELESTE | reporter.nih.gov |
| Complement-mediated anti-pneumococcal functions of C-reactive protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,480,000 | February 5, 2020 | January 31, 2026 | SINGH, SANJAY KUMAR | reporter.nih.gov |
| Development of broadly-protective vaccines for influenza B viruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,475,893 | July 1, 2023 | June 30, 2027 | KAWAOKA, YOSHIHIRO | reporter.nih.gov |
| Airway Prevotella enhance innate immune-mediated protection against lung infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,475,007 | March 20, 2023 | February 29, 2028 | CLARK, SARAH E | reporter.nih.gov |
| Structures and Dynamics of Proton and Cation-Dependent Channels and Transporters | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,474,187 | September 30, 2009 | June 30, 2025 | HONG, MEI | reporter.nih.gov |
| Reducing Infection Susceptibility by Immune Function Restoration in Spinal Cord Injury | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,459,520 | July 1, 2020 | June 30, 2025 | SCHWAB, JAN | reporter.nih.gov |
| Disease Mechanisms of Prenatal and Pediatric Acquired Hydrocephalus | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,458,488 | April 1, 2020 | March 31, 2026 | CONOVER, JOANNE C | reporter.nih.gov |
| Soluble adenylyl cyclases in lung endothelial tauopathy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,451,396 | March 20, 2023 | February 28, 2027 | STEVENS, TROY | reporter.nih.gov |
| Effects of Vaccination on Acute and Post-Acute Respiratory Viral Infection Outcomes in Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,442,898 | June 13, 2025 | May 31, 2030 | WERBEL, WILLIAM | reporter.nih.gov |
| Motivational Interviewing Training to Promote COVID-19 and Influenza Vaccination (MI-VAX): What Providers Need and Patients Want | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $1,432,670 | June 27, 2024 | January 31, 2029 | FISHER, KIMBERLY | reporter.nih.gov |
| Inflammatory Organ Injury after Pneumonia-Derived Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,430,432 | July 1, 2024 | May 31, 2029 | JEYASEELAN, SAMITHAMBY | reporter.nih.gov |
| NK cell inflammation resolution circuits in pediatric RSV infection | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,426,494 | December 1, 2023 | November 30, 2028 | DUVALL, MELODY G. | reporter.nih.gov |
| Antibody mediated immunity against Klebsiella pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,424,123 | December 1, 2023 | October 31, 2028 | HARRIS, JASON B | reporter.nih.gov |
| Endothelial antigen presentation to T cells as a pathogenic mechanism in influenza-induced acute lung injury | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,412,604 | March 15, 2021 | February 28, 2027 | ZHANG, LIANGHUI | reporter.nih.gov |
| Airway metabolites shape susceptibility to pneumonia | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,408,116 | April 1, 2024 | March 31, 2028 | PRINCE, ALICE S | reporter.nih.gov |
| Sphingolipid signaling in the endothelium during viral host defense | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,405,202 | January 1, 2024 | December 31, 2027 | HLA, TIMOTHY TUN | reporter.nih.gov |
| Negative regulation of innate immunity in influenza virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,396,060 | November 13, 2023 | October 31, 2028 | LI, JIAN-DONG | reporter.nih.gov |
| Overcome immunodominance to support the development of universal influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,395,922 | August 28, 2024 | June 30, 2029 | LUO, WEI | reporter.nih.gov |
| Longitudinal dynamics of protection after influenza infection and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,395,852 | July 1, 2019 | June 30, 2025 | COBEY, SARAH | reporter.nih.gov |
| Adenoviral Vector-based Pandemic Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,393,690 | July 1, 2005 | April 30, 2028 | MITTAL, SURESH K | reporter.nih.gov |
| Real-time predictive modeling for public health departments to control infectious diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,389,825 | July 1, 2023 | July 31, 2027 | LO, NATHAN | reporter.nih.gov |
| Epitope and mechanistic correlates of broadly protective human antibodies for pneumococcal infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,369,933 | November 1, 2022 | October 31, 2028 | MOUSA, JARROD | reporter.nih.gov |
| Shifting immunodominance of humoral immunity against influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,354,521 | August 22, 2023 | July 31, 2028 | GUTHMILLER, JENNA | reporter.nih.gov |
| High resolution profiling and computational modeling of influenza virus-immune dynamics during natural infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,352,292 | February 1, 2025 | January 31, 2030 | BROOKE, CHRISTOPHER BYRON | reporter.nih.gov |
| The role of Bik in the replication and severity of influenza A virus | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,345,904 | January 1, 2021 | December 31, 2026 | MEBRATU, YOHANNES AFEWORK | reporter.nih.gov |
| Dime la VerDAD (Verify, Debunk, and Disseminate) | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2024 | $1,339,601 | July 10, 2023 | September 15, 2024 | DEL RIOS, MARINA | reporter.nih.gov |
| Vaccine immunity and inflammation in the aging person living with HIV | NIH | National Institute on Aging | 2024 to 2025 | $1,337,478 | July 15, 2024 | June 30, 2029 | FROSCH, ANNE ELIZABETH PARKER | reporter.nih.gov |
| A universal intranasal nanoengineered therapy against airborne RNA viruses | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $1,328,784 | July 3, 2024 | April 30, 2028 | MAHAJAN, VINAY SUBHASH | reporter.nih.gov |
| Synthetic multi-component influenza vaccines to elicit broad immunity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,325,514 | December 19, 2023 | October 31, 2028 | BOONS, GEERT-JAN | reporter.nih.gov |
| B and Tfh cell dynamics underlying durable antibody responses to flu vaccine in children | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,297,795 | April 1, 2024 | February 28, 2029 | SINGH, HARINDER | reporter.nih.gov |
| Structure-guided neutralizing antibodies developed using EpiVolve technology | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,291,874 | May 5, 2023 | May 31, 2026 | LI, XIAOFENG | reporter.nih.gov |
| Novel strategies to mitigate cardiac damage and dysfunction following invasive pneumococcal disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,289,472 | May 25, 2024 | June 1, 2025 | LAL, HIND | reporter.nih.gov |
| Advancing our knowledge of viral membrane fusion and of IDP-membrane interactions by ESR | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,283,934 | February 1, 2023 | January 31, 2028 | FREED, JACK H | reporter.nih.gov |
| Intersection of Severe Respiratory Infection and Viral Latency | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,280,794 | June 12, 2024 | April 30, 2029 | STEED, ASHLEY | reporter.nih.gov |
| Small viral RNAs as determinants of influenza A virus pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,271,250 | February 4, 2020 | January 31, 2026 | TENOEVER, BENJAMIN R. | reporter.nih.gov |
| Glypicans in Bacterial Lung Infection | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,247,722 | April 1, 2024 | March 31, 2028 | PARK, PYONG WOO | reporter.nih.gov |
| Towards a predictive understanding of influenza immunity through experimental data integration, iterative model development, and rigorous assessment of model quality | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,246,617 | December 19, 2024 | November 30, 2029 | PETERS, BJOERN | reporter.nih.gov |
| Impact of Senolytics on Aged Vaccine Responses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,244,166 | November 1, 2022 | October 31, 2027 | BARTLEY, JENNA | reporter.nih.gov |
| Mechanisms of hypervirulent Klebsiella pneumoniae gastrointestinal colonization and dissemination | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,240,075 | June 14, 2023 | May 31, 2025 | ZAFAR, MUHAMMAD AMMAR | reporter.nih.gov |
| Immune signatures of vaccine responses in children with sickle cell disease | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,228,468 | December 1, 2023 | October 31, 2028 | YILDIRIM, INCI BURCIN | reporter.nih.gov |
| Mitochondrial metabolism controls alveolar epithelial cell fate | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,227,550 | September 1, 2024 | August 31, 2029 | HAN, SEUNGHYE | reporter.nih.gov |
| Computational Models of Adaptive Immunity to Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,225,986 | January 23, 2025 | December 31, 2029 | COBEY, SARAH | reporter.nih.gov |
| Effects of wildfire smoke on respiratory antiviral defense responses | NIH | National Institute of Environmental Health Sciences | 2024 to 2025 | $1,217,903 | August 10, 2024 | May 31, 2029 | REBULI, MEGHAN ELIZABETH | reporter.nih.gov |
| Host dependence of influenza A virus spatio-temporal dynamics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,214,178 | December 5, 2016 | August 31, 2029 | LOWEN, ANICE C | reporter.nih.gov |
| Defining the four major routes of MHC class II antigen processing and presentation with influenza antigens | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,213,296 | June 1, 2024 | April 30, 2029 | EISENLOHR, LAURENCE CRANE | reporter.nih.gov |
| Identifying critical determinants of vaccine-induced cellular and humoral immunity from birth through childhood in HIV-exposed and unexposed children | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,202,470 | November 20, 2023 | October 31, 2027 | SLYKER, JENNIFER ANN | reporter.nih.gov |
| HIV-1 Env gp160 maturation in the Golgi apparatus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,199,250 | May 10, 2023 | April 30, 2028 | ZHENG, YONG-HUI | reporter.nih.gov |
| Unravelling highly pathogenic influenza virus emergence | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,196,018 | August 1, 2023 | July 31, 2028 | RICHARD, MATHILDE | reporter.nih.gov |
| Machine Learning to Modulate Influenza Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,195,056 | May 19, 2025 | April 30, 2030 | MEILER, JENS | reporter.nih.gov |
| Extrafollicular B cell response regulation during influenza infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,193,272 | June 10, 2024 | May 31, 2029 | BAUMGARTH, NICOLE | reporter.nih.gov |
| How Distinct Age-Associated B Cell Subsets Can Protect the Aged from Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,172,336 | August 19, 2024 | July 31, 2029 | SWAIN, SUSAN L | reporter.nih.gov |
| Influenza Modeling of Correlates of Protection for Optimal Immune Dynamics and Evolution. | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,171,832 | December 24, 2024 | November 30, 2029 | MEDINA SILVA, RAFAEL A. | reporter.nih.gov |
| Floss: a novel method for oral mucosal vaccination | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,169,988 | August 1, 2024 | April 30, 2029 | GILL, HARVINDER SINGH | reporter.nih.gov |
| The MUltidimenSional phenotyping In Critical care (MUSIC) Consortium: A pathway to precision medicine at the bedside | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,162,536 | May 1, 2023 | April 30, 2029 | WARE, LORRAINE B | reporter.nih.gov |
| Genetic and biophysical mechanisms that control influenza virus cellular multiplicity of infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,155,422 | February 16, 2023 | January 31, 2028 | VAHEY, MICHAEL D | reporter.nih.gov |
| Pathogenic role of IL-17 response in Streptococcus pneumoniae nasopharyngeal pathogenesis during an influenza virus co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,152,158 | December 3, 2019 | November 30, 2025 | KHAN, NADEEM | reporter.nih.gov |
| Protein Transport Across Membrane by Bacterial Pathogens | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,149,661 | July 7, 2023 | April 30, 2028 | DURIE, CLARISSA LYNN | reporter.nih.gov |
| Defining the Role of the Plasminogen Activator Protease in the Early Events that Establish Primary Pneumonic Plague | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,149,651 | May 1, 2021 | July 31, 2024 | PECHOUS, ROGER D | reporter.nih.gov |
| Colorado APS Clinical Center | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,144,687 | May 1, 2023 | April 30, 2029 | MOSS, MARC | reporter.nih.gov |
| Phenotyping ARDS, Pneumonia, and Sepsis over time to elucidate shared and distinct trajectories ofillness and recovery | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,144,421 | May 1, 2023 | April 30, 2029 | MEYER, NUALA JENNINGS | reporter.nih.gov |
| Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,140,945 | May 1, 2023 | April 30, 2029 | HYZY, ROBERT C | reporter.nih.gov |
| The Intermountain West-Atlantic Center (InterACT) for the APS Phenotyping Consortium | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,133,343 | May 1, 2023 | April 30, 2029 | BROWN, SAMUEL MORRIS | reporter.nih.gov |
| The vital role of T403 phosphorylation of STAT2 in post-viral bacterial pneumonia | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,127,000 | March 20, 2024 | February 28, 2029 | WANG, YUXIN | reporter.nih.gov |
| PRC2 independent role of Ezh2 in regulation of basal cell dynamics post-influenza virus infection | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,126,282 | September 1, 2024 | May 31, 2029 | YAO, CHANGFU | reporter.nih.gov |
| Protecting Endogenous Recovery from the "Infectious Insult" in Spinal Cord Injury | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,121,721 | September 20, 2024 | August 31, 2029 | FILOUS, ANGELA R | reporter.nih.gov |
| Atlas of efflux and permeation determinants to advance antibacterial therapeutic discovery | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,120,070 | July 21, 2025 | June 30, 2030 | ZGURSKAYA, HELEN I | reporter.nih.gov |
| Molecular Phenotyping of ARDS, Pneumonia, and Sepsis using Latent Class Analysis and Metagenomic Sequencing | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,118,088 | May 1, 2023 | April 30, 2029 | CALFEE, CAROLYN | reporter.nih.gov |
| Mechanisms of host protection against pathogen-associated proteases in acute lung injury | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,115,035 | September 1, 2016 | August 31, 2025 | LEE, JANET SOJUNG | reporter.nih.gov |
| The role of circadian clock proteins in innate and adaptive immunity | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,096,430 | September 26, 2022 | July 31, 2026 | ROSENGART, MATTHEW RANDALL | reporter.nih.gov |
| Armed nanobodies as anti-infectives and anti-tumor agents | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,085,800 | July 19, 2024 | May 31, 2029 | WU, HAO | reporter.nih.gov |
| Multiscale Modeling of Influenza Neutralizing Antibody and Fc Effector Biology | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,082,429 | December 19, 2024 | November 30, 2029 | CHAN, CLIBURN C | reporter.nih.gov |
| Lung-derived complement in pneumonia | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,073,597 | May 19, 2023 | April 30, 2028 | KULKARNI, HRISHIKESH SATISH | reporter.nih.gov |
| Inducible HMGB1 antagonist for viral-induced acute lung injury. | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,068,694 | August 16, 2023 | July 31, 2025 | BLANCO, JORGE C | reporter.nih.gov |
| CD4+ T cell Immunity in the Respiratory Tract | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,063,324 | June 5, 2025 | May 31, 2032 | KOLLS, JAY K | reporter.nih.gov |
| Biomimetic nanoparticles to enhance the breadth of influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,062,524 | August 7, 2020 | July 31, 2025 | WU, MEI X | reporter.nih.gov |
| The role of Nrf2 in T cell function and influenza | NIH | National Institute of Environmental Health Sciences | 2024 to 2025 | $1,053,331 | July 6, 2024 | April 30, 2029 | ROCKWELL, CHERYL ELIZABETH | reporter.nih.gov |
| IND-enabling studies of an intranasal, single-replication M2SR influenza vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,048,815 | August 1, 2015 | June 30, 2026 | BILSEL, PAMUK | reporter.nih.gov |
| The BLAAST Trial: Bangladesh Lung Auscultation AI for Antibiotic Stewardship Randomized Controlled Trial | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,038,588 | September 1, 2024 | May 31, 2029 | MCCOLLUM, ERIC DOUGLASS | reporter.nih.gov |
| The Role of TRIM6 and Ubiquitin in Influenza Virus-Induced Pathology | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,032,987 | May 13, 2021 | April 30, 2027 | RAJSBAUM, RICARDO | reporter.nih.gov |
| Age related loss of immune resilience during response to severe respiratory viral infections | NIH | National Institute on Aging | 2024 to 2025 | $1,028,435 | July 1, 2024 | April 30, 2029 | SEGAL, LEOPOLDO NICOLAS | reporter.nih.gov |
| Establishing and Implementing Pneumonia Diagnosis in ED Older Adults: A Mixed Methods Approach | NIH | National Institute on Aging | 2022 to 2025 | $1,018,845 | September 15, 2022 | June 30, 2027 | BUCK, KATHERINE HUNOLD | reporter.nih.gov |
| Development of IN-003PI as passive immunization against human metapneumovirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,013,468 | September 1, 2025 | July 31, 2028 | HUTCHINS, JEFF T | reporter.nih.gov |
| Dissecting the viral and host constraints that govern influenza virus antigenic evolution | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,013,305 | December 1, 2023 | October 31, 2028 | BROOKE, CHRISTOPHER BYRON | reporter.nih.gov |
| IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,013,003 | August 1, 2025 | July 31, 2028 | HUTCHINS, JEFF T | reporter.nih.gov |
| AT191: An inhaled & precision RNA therapeutic with pan-variant SARS-CoV-2 efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,004,473 | September 10, 2025 | August 31, 2028 | WEINBERGER, ARIEL | reporter.nih.gov |
| A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,000,000 | January 1, 2022 | August 31, 2028 | HARDING, CHRISTIAN | reporter.nih.gov |
| Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,000,000 | July 3, 2023 | December 31, 2026 | DAVENPORT, GREGORY | reporter.nih.gov |
| Causal Inference in Infectious Disease Prevention Studies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $982,276 | December 1, 2009 | May 31, 2026 | HUDGENS, MICHAEL G | reporter.nih.gov |
| Innate Control of Adaptive Immunity to SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $968,772 | June 1, 2021 | May 31, 2026 | GOLDMAN-ISRAELOW, BENJAMIN | reporter.nih.gov |
| Protection of at-risk low birth weight infants against influenza via maternal antibody | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $942,300 | June 1, 2021 | May 31, 2026 | KACHIKIS, ALISA | reporter.nih.gov |
| Role of ERK1/2 signaling in SARS-CoV-2 -induced dysregulated immunity and lung pathology. | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $930,578 | September 6, 2024 | June 30, 2029 | CHANNAPPANAVAR, RUDRAGOUDA | reporter.nih.gov |
| Dissecting the host-plasmid interplay to unravel the spread of ESBL-producing K. pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $874,998 | August 13, 2025 | June 30, 2030 | KREISWIRTH, BARRY NEAL | reporter.nih.gov |
| Infant Protection from Influenza through Maternal Influenza Immunization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $874,965 | June 1, 2021 | May 31, 2027 | RICK, ANNE-MARIE | reporter.nih.gov |
| Pediatric Recovery After Sepsis Treatment in the Pediatric Intensive Care Unit | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $859,700 | September 1, 2022 | August 31, 2026 | PERRY-EADDY, MALLORY A | reporter.nih.gov |
| The basis of Influenza A virus strain-dependent reassortment potential | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $858,639 | February 14, 2024 | January 31, 2029 | DIAZ, SAMUEL L | reporter.nih.gov |
| Defining the Role of ANKEF1 in Ciliary Function and Host Defense Against Influenza Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $856,791 | September 12, 2025 | August 31, 2026 | MIORIN, LISA | reporter.nih.gov |
| Predisposition for Lung Injury in Sepsis Survival | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $847,800 | May 1, 2021 | April 30, 2026 | DENSTAEDT, SCOTT JOHN | reporter.nih.gov |
| Explore a key nucleotide synthesis enzyme to develop a broad-spectrum antiviral therapy. | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $831,235 | August 21, 2025 | July 31, 2030 | FENG, PINGHUI | reporter.nih.gov |
| The NF-kappaB modulator PDLIM2 as an intrinsic checkpoint of alveolar macrophages critical for lung innate immunity, inflammation and diseases | NIH | National Heart, Lung, and Blood Institute | 2025 | $829,998 | April 1, 2025 | January 31, 2029 | QU, ZHAOXIA | reporter.nih.gov |
| Epitope and mechanistic correlates of broadly protective human antibodies for pneumococcal infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $828,509 | November 1, 2022 | November 30, 2023 | MOUSA, JARROD | reporter.nih.gov |
| Targeting Angiopoietin-like 4 (ANGPTL4) in Severe Community Acquired Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2025 | $827,909 | April 4, 2025 | January 31, 2029 | BHATRAJU, PAVAN KUMAR | reporter.nih.gov |
| Beta-Lactamase Inhibitors Sensitize Multidrug-Resistant Gram-negative Pathogens to Innate Immune Clearance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $820,829 | April 1, 2020 | March 31, 2026 | ULLOA, ERLINDA ROSE | reporter.nih.gov |
| Lung vascular ILC3 subpopulation in anti-bacteria immunity and vasculature regeneration | NIH | National Heart, Lung, and Blood Institute | 2025 | $814,387 | August 1, 2025 | April 30, 2029 | HUANG, YUEFENG | reporter.nih.gov |
| Assessing functional immunity to influenza infection by quantifying BCR binding avidities | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $811,009 | November 13, 2024 | October 31, 2029 | GEORGE, STEVEN CARL | reporter.nih.gov |
| Mechanisms of regulatory T-cell mediated endothelial repair following viral pneumonia in aged hosts | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $805,882 | September 20, 2021 | August 31, 2026 | MORALES-NEBREDA, LUISA | reporter.nih.gov |
| The oxidation of heme-carrying proteins in the pathophysiology of pneumococcal disease | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $805,442 | November 20, 2023 | October 31, 2028 | VIDAL, JORGE EUGENIO | reporter.nih.gov |
| Pulmonary gamma-delta T cells in lung infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $804,060 | June 15, 2021 | May 31, 2027 | WRIGHT, SHELTON WILEY | reporter.nih.gov |
| Optimizing Medications and Lung Health in People with HIV through Pharmacist-led Proactive E-Consults (OPTIMIZE Lung-HIV) | NIH | National Heart, Lung, and Blood Institute | 2025 | $803,801 | August 15, 2025 | May 31, 2030 | CROTHERS, KRISTINA ANNE | reporter.nih.gov |
| Detrimental Effects of B-Cell-Th17 Axis in Antiviral Immunity in Smokers. | NIH | National Heart, Lung, and Blood Institute | 2025 | $799,998 | September 1, 2025 | May 31, 2030 | KHERADMAND, FARRAH | reporter.nih.gov |
| Protecting Patients with Glomerular Disease from Vaccine-Preventable Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $795,246 | February 15, 2022 | January 31, 2027 | GLENN, DOREY | reporter.nih.gov |
| The interplay of maternal antibody and newborn vaccine responses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $793,102 | April 17, 2025 | March 31, 2030 | ALEXANDER-MILLER, MARTHA ANN | reporter.nih.gov |
| Identifying Novel Roles and the Therapeutic Potential of the Thrombin Receptor Protease Activated Receptor-1 (PAR1) in Lung Lymphatic Function and Acute Respiratory Distress Syndrome | NIH | National Heart, Lung, and Blood Institute | 2025 | $791,503 | September 15, 2025 | June 30, 2029 | REED, HASINA OUTTZ | reporter.nih.gov |
| iPSC-derived macrophages as a model to study the genetic basis of inter-individual variation in immune responses to pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $785,511 | January 24, 2025 | December 31, 2029 | BARREIRO, LUIS BRUNO | reporter.nih.gov |
| Elucidating the genotypic determinants and phenotypic effects of polymyxin resistance in Klebsiella pneumoniae utilizing CRISPR-Cas9 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $769,824 | July 1, 2020 | June 30, 2026 | MCCONVILLE, THOMAS HOWE | reporter.nih.gov |
| Elucidating Olfactory Epithelial Anti-Viral Responses in Persistent Post-Viral Olfactory Dysfunction | NIH | National Institute on Deafness and Other Communication Disorders | 2022 to 2025 | $767,492 | February 1, 2022 | January 31, 2027 | YAN, CAROL H | reporter.nih.gov |
| Migration and resolution, lung microenvironment and mechanisms: examining the diverse responses of neutrophils during S. pneumoniae pneumonia and acute lung injury | NIH | National Heart, Lung, and Blood Institute | 2025 | $759,983 | May 15, 2025 | February 28, 2029 | DOERSCHUK, CLAIRE M | reporter.nih.gov |
| Molecular Basis for the TREX-2 mRNA Nuclear Export Pathway | NIH | National Institute of General Medical Sciences | 2025 | $758,594 | September 1, 2025 | August 31, 2027 | FONTOURA, BEATRIZ MA | reporter.nih.gov |
| Rational design of a unique vaccine for emerging pandemic coronaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $755,225 | December 6, 2024 | November 30, 2029 | QIAO, LIANG | reporter.nih.gov |
| Pathogenic mechanisms of chronic lung sequelae following respiratory viral infection | NIH | National Heart, Lung, and Blood Institute | 2025 | $754,729 | August 10, 2025 | May 31, 2029 | ZHANG, LIANGHUI | reporter.nih.gov |
| Identifying mechanisms by which metformin regulates T cell responses in obesity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $753,296 | December 20, 2024 | November 30, 2029 | MACIVER, NANCIE | reporter.nih.gov |
| Putting Implementation into context to advance the management of mechanically ventilated patients. | NIH | National Heart, Lung, and Blood Institute | 2025 | $748,970 | August 15, 2025 | May 31, 2029 | KERLIN, MEETA PRASAD | reporter.nih.gov |
| Refining our understanding of antimicrobial peptide mediated disruption of the Klebsiella pneumoniae capsule | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $747,000 | August 24, 2021 | March 31, 2027 | FLEEMAN, RENEE | reporter.nih.gov |
| Mechanisms of GM-CSF-mediated metabolic regulation of monocyte function for control of pulmonary infection | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $747,000 | August 5, 2023 | July 31, 2026 | LIU, XIN | reporter.nih.gov |
| Lung epithelial cell reprogramming by CD4 T cells | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $746,997 | April 1, 2023 | March 31, 2026 | SHENOY, ANUKUL T | reporter.nih.gov |
| Exploring the role of T cells in protection from respiratory virus transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $744,977 | February 1, 2025 | January 31, 2030 | KOHLMEIER, JACOB E | reporter.nih.gov |
| Oseltamivir Use and Risk of Serious Neuropsychiatric Adverse Events in Children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $740,087 | March 1, 2022 | February 28, 2026 | ANTOON, JAMES W | reporter.nih.gov |
| Mechanistic bases of strain-specific virus-host interactions | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $729,993 | February 1, 2024 | January 31, 2029 | CHO, JAE HYUN | reporter.nih.gov |
| Impact of Diet Induced Obesity on Acute Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $725,760 | January 15, 2022 | January 17, 2025 | PLATAKI, MARIA | reporter.nih.gov |
| Monocyte-derived galectin-1 promotes tissue-resident memory T cell response | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $722,958 | November 22, 2024 | October 31, 2029 | KIM, MINSOO | reporter.nih.gov |
| Pulmonary neuroimmune determinants of immunoglobulin production against pneumonia | NIH | National Heart, Lung, and Blood Institute | 2025 | $718,661 | August 1, 2025 | April 30, 2030 | JENDZJOWSKY, NICHOLAS | reporter.nih.gov |
| Mentoring in transmission of influenza and strategies for prevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $714,408 | February 3, 2020 | October 31, 2025 | GRIJALVA, CARLOS G | reporter.nih.gov |
| REINVIGORATE: Repeated Enhanced INfluenza Vaccines In Geriatrics of a Randomised trial for Antibody and T cell Effects | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $711,626 | April 11, 2024 | March 31, 2029 | DOAK, SOPHIE ALESSANDRA VALKENBURG | reporter.nih.gov |
| Glycan-Mediated Impacts on the Mucus Barrier Towards Respiratory Viruses | NIH | National Heart, Lung, and Blood Institute | 2025 | $711,144 | September 1, 2025 | June 30, 2029 | SCULL, MARGARET ADELE | reporter.nih.gov |
| Immunity in the Nose to inFLUENza: Correlates of Efficacy (INFLUENCE) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $701,638 | May 4, 2023 | April 30, 2025 | THWAITES, RYAN | reporter.nih.gov |
| Community - based behavioral intervention to increase COVID - 19 and influenza vaccination for African American/ Black and Latino persons: An optimization randomized controlled trial | NIH | National Institute on Minority Health and Health Disparities | 2024 | $688,573 | September 22, 2024 | April 1, 2025 | GWADZ, MARYA | reporter.nih.gov |
| 2/2 WIN Ratio Analysis to Determine a Strategy of Non-Invasive SUpport for Respiratory Failure in the EmeRgency Department (WINDSURFER) | NIH | National Heart, Lung, and Blood Institute | 2025 | $688,047 | September 1, 2025 | August 31, 2031 | DURKALSKI, VALERIE L | reporter.nih.gov |
| Nosocomial pneumonia impairs the cerebrovasculature | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $684,527 | May 16, 2024 | May 2, 2025 | NELSON, AMY R | reporter.nih.gov |
| Targeting Estrogenic pathways in Tregs to promote ARDS resolution - 5R01HL163881 | NIH | National Heart, Lung, and Blood Institute | 2025 | $684,280 | August 15, 2025 | May 31, 2027 | D'ALESSIO, FRANCO RAFAEL | reporter.nih.gov |
| Extending neutrophil survival in neutropenia-related pneumonia | NIH | National Heart, Lung, and Blood Institute | 2025 | $676,748 | July 1, 2025 | March 31, 2029 | LUO, HONGBO R | reporter.nih.gov |
| Spatial and Temporal Adjuvant Delivery for Skin mRNA Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $676,666 | September 3, 2025 | August 31, 2030 | WU, MEI X | reporter.nih.gov |
| Role of respiratory viral infections and inflammation in promoting metastatic outgrowth in the lung | NIH | National Cancer Institute | 2025 | $672,011 | March 1, 2025 | February 28, 2030 | DEGREGORI, JAMES V | reporter.nih.gov |
| The effect of household air pollution on lung function growth in infants with pneumonia in sub-Saharan Africa. | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $670,862 | March 14, 2024 | February 28, 2025 | MOSCHOVIS, PETER P | reporter.nih.gov |
| Characterization and optimization of single dose, thermostable and durable vaccine platform towards increased clinical acceptance | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $668,569 | August 23, 2024 | June 30, 2029 | ZABALETA, NEREA | reporter.nih.gov |
| Hospital adaptation and resiliency for infected and uninfected patients during respiratory viral surge events: from seasonal influenza to COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $664,475 | December 15, 2021 | November 30, 2026 | ANESI, GEORGE L | reporter.nih.gov |
| Task A04: Mouse Models for Evaluation of Therapeutics against Human Seasonal Influenza and Avian Influenza Strains with Pandemic Potential | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $663,068 | September 24, 2024 | September 23, 2025 | COOK, MIKAYLA | reporter.nih.gov |
| The role of HMGB1 in the lung response to bacterial injury | NIH | National Heart, Lung, and Blood Institute | 2025 | $656,988 | August 1, 2025 | April 30, 2030 | MESSER, JEANNETTE SOPHIA | reporter.nih.gov |
| Full Spectrum Cell Sorter with Imaging Enhancement for Boston University Flow Cytometry Core Facility | NIH | Office of the Director, National Institutes of Health | 2025 | $656,148 | April 15, 2025 | April 14, 2026 | BELKINA, ANNA | reporter.nih.gov |
| Intrapulmonary itaconate as a host-protective metabolite during ER Stress and Klebsiella pneumoniae infection | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $642,944 | April 1, 2022 | March 31, 2027 | SUBER, TOMEKA L | reporter.nih.gov |
| Impaired Pneumococcal Antibody Function and Exacerbations of Chronic Obstructive Pulmonary Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $642,128 | January 1, 2022 | December 31, 2026 | LAFON, DAVID CARDY | reporter.nih.gov |
| Mechanisms of CD8 TRM-mediated protection against respiratory virus transmission | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $640,735 | July 26, 2024 | June 30, 2025 | KOHLMEIER, JACOB E | reporter.nih.gov |
| CD38, T cells and post viral lung sequelae during aging | NIH | National Institute on Aging | 2025 | $639,740 | December 15, 2024 | November 30, 2029 | SUN, JIE | reporter.nih.gov |
| Implementation research to improve the uptake of influenza vaccination in CKD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $627,765 | August 4, 2021 | March 10, 2025 | ISHIGAMI, JUNICHI | reporter.nih.gov |
| Gene regulatory network of memory B cell and long-lived plasma cell differentiation | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $625,348 | July 3, 2025 | June 30, 2030 | ROY, KOUSHIK | reporter.nih.gov |
| Developing mRNAdesigner tool package for optimization of mRNA sequence | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $624,000 | September 30, 2024 | June 30, 2028 | ZHOU, XIAOBO | reporter.nih.gov |
| Targeted genetic engineering of B cells to induce protective antibody responses to pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $618,943 | July 5, 2022 | June 30, 2027 | ADAIR, JENNIFER EILEEN | reporter.nih.gov |
| Eosinophils as Effectors of Antibacterial Immunity in the Lungs | NIH | National Heart, Lung, and Blood Institute | 2024 | $615,455 | September 1, 2024 | June 30, 2028 | SAMARASINGHE, AMALI | reporter.nih.gov |
| A redox-sensitive switch in the macrophage nucleus regulates acute phaseinflammatory injury | NIH | National Heart, Lung, and Blood Institute | 2025 | $613,814 | June 1, 2022 | May 31, 2027 | BONINI, MARCELO G. | reporter.nih.gov |
| Eosinophils as Effectors of Antibacterial Immunity in the Lungs | NIH | National Heart, Lung, and Blood Institute | 2025 | $613,501 | September 1, 2024 | June 30, 2028 | SAMARASINGHE, AMALI E | reporter.nih.gov |
| The Role of Ariadne RBR E3 ubiquitin protein ligase 2 (ARIH2) in influenza A virus replication and pathogenesis in the airway epithelial cells | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $605,778 | July 7, 2025 | June 30, 2030 | MEBRATU, YOHANNES AFEWORK | reporter.nih.gov |
| Novel Hybrid Computational Models to Disentangle Complex Immune Responses | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $600,000 | September 26, 2023 | August 31, 2027 | HERNANDEZ VARGAS, ESTEBAN ABELARDO | reporter.nih.gov |
| Mechanisms of Klebsiella pneumoniae gastrointestinal colonization | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $599,768 | June 14, 2023 | May 31, 2029 | ZAFAR, MUHAMMAD AMMAR | reporter.nih.gov |
| A more durable and universal adjuvanted influenza vaccine through synthetic biology | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $599,526 | June 1, 2025 | May 31, 2027 | KEMPINSKI, CHASE | reporter.nih.gov |
| MRNA VACCINE DEVELOPMENT | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $594,566 | September 1, 2024 | August 31, 2026 | ANDRIANOVA, KATERINA | reporter.nih.gov |
| Mechanisms by which NS1 and NEP govern the influenza lifecycle | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $587,885 | September 18, 2025 | August 31, 2030 | PETIT, CHAD | reporter.nih.gov |
| Host factors influencing early clearance of Streptococcus pneumoniae from the middle ear following invasion from the nasopharynx | NIH | National Institute on Deafness and Other Communication Disorders | 2022 to 2024 | $583,125 | February 1, 2022 | July 31, 2025 | CLARK, SARAH E | reporter.nih.gov |
| Individualizing Steroid Use in Pneumonia (Supplement) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $582,229 | June 1, 2023 | July 31, 2026 | ODEYEMI, YEWANDE | reporter.nih.gov |
| Use of probiotics to modulate antimicrobial peptide signaling in the neonatal innate immune response to influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $554,786 | September 17, 2025 | August 31, 2027 | CAREY, ALISON J | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York, NY | 15 | $158 million | 0 | $0 |
| The Emmes Company, LLC | Rockville, MD | 1 | $150.3 million | 0 | $0 |
| Duke University | Durham, NC | 14 | $140.5 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 12 | $130.9 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 8 | $84.7 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 21 | $79 million | 0 | $0 |
| Emory University | Atlanta, GA | 26 | $75.6 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 9 | $72 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 20 | $49.3 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 4 | $39.1 million | 0 | $0 |
| University of Chicago | Chicago, IL | 12 | $34.8 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 19 | $30.1 million | 0 | $0 |
| University of Washington | Seattle, WA | 14 | $29.8 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 7 | $27.5 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 20 | $24.3 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 7 | $24.3 million | 0 | $0 |
| Digital Infuzion, Inc. | Rockville, MD | 2 | $22.8 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 14 | $21.8 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 1 | $21.2 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 13 | $19.7 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 14 | $18.8 million | 0 | $0 |
| Ohio State University | Columbus, OH | 14 | $18.1 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 6 | $17.9 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 8 | $17.1 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 3 | $15.9 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 10 | $15.7 million | 0 | $0 |
| Washington University | Saint Louis, MO | 12 | $15.3 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 7 | $14.8 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 14 | $14.2 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 7 | $14.2 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 1 | $14.2 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 13 | $14.2 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 7 | $13.9 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 8 | $13.8 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 17 | $12.6 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 11 | $12.4 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 10 | $12.2 million | 0 | $0 |
| Rockefeller University | New York, NY | 3 | $11.9 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 11 | $11.7 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 2 | $11.7 million | 0 | $0 |
| University of Montana | Missoula, MT | 1 | $11.6 million | 0 | $0 |
| Versatope Therapeutics, Inc. | Lowell, MA | 1 | $10.9 million | 0 | $0 |
| Regents of the University of Idaho | Moscow, ID | 2 | $10.3 million | 0 | $0 |
| Stanford University | Stanford, CA | 8 | $10.2 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 6 | $9.9 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 6 | $9.9 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 5 | $9 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 6 | $8.7 million | 0 | $0 |
| Inhalon Biopharma, Inc. | Morrisville, NC | 5 | $8.7 million | 0 | $0 |
| Yale University | New Haven, CT | 9 | $8.4 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 5 | $8.1 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 5 | $8 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 6 | $7.5 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 4 | $7.5 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 6 | $7.4 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 6 | $7.4 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 3 | $7.4 million | 0 | $0 |
| University of South Alabama | Mobile, AL | 7 | $7.2 million | 0 | $0 |
| University of Maryland Baltimore County | Baltimore, MD | 1 | $7.1 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 7 | $7.1 million | 0 | $0 |
| Washington State University | Pullman, WA | 1 | $6.7 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 3 | $6.7 million | 0 | $0 |
| TSRL, Inc. | Ann Arbor, MI | 3 | $6.5 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 5 | $6.5 million | 0 | $0 |
| Lurie Children's Hospital of Chicago | Chicago, IL | 4 | $6.4 million | 0 | $0 |
| University of California-San Diego Scripps Inst of Oceanography | La Jolla, CA | 1 | $6.4 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 5 | $6.3 million | 0 | $0 |
| Orlance, Inc. | Seattle, WA | 3 | $6.3 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 4 | $6.2 million | 0 | $0 |
| Nubad, LLC | Greer, SC | 2 | $6.2 million | 0 | $0 |
| Novobiotic Pharmaceuticals, LLC | Cambridge, MA | 1 | $6.2 million | 0 | $0 |
| Inimmune Corporation | Missoula, MT | 1 | $5.9 million | 0 | $0 |
| Northeastern University | Boston, MA | 2 | $5.9 million | 0 | $0 |
| International Aids Vaccine Initiative | New York, NY | 1 | $5.6 million | 0 | $0 |
| University of Rochester | Rochester, NY | 6 | $5.5 million | 0 | $0 |
| Greffex, Inc. | Aurora, CO | 1 | $5.5 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 4 | $5.4 million | 0 | $0 |
| Curza INC | Salt Lake City, UT | 2 | $4.9 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 1 | $4.8 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 3 | $4.7 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 3 | $4.6 million | 0 | $0 |
| The University of Central Florida Board of Trustees | Orlando, FL | 3 | $4.5 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 2 | $4.5 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 1 | $4.2 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 3 | $4.2 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 2 | $4.1 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 3 | $4 million | 0 | $0 |
| Iowa State University | Ames, IA | 2 | $3.9 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 3 | $3.9 million | 0 | $0 |
| Louisiana State University | Baton Rouge, LA | 4 | $3.8 million | 0 | $0 |
| New York Blood Center | New York, NY | 1 | $3.7 million | 0 | $0 |
| Florida State University | Tallahassee, FL | 3 | $3.7 million | 0 | $0 |
| Vaxnewmo, LLC | Saint Louis, MO | 2 | $3.6 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 4 | $3.5 million | 0 | $0 |
| University of Tennessee Health Sci CTR | Memphis, TN | 2 | $3.5 million | 0 | $0 |
| University of Florida | Gainesville, FL | 2 | $3.4 million | 0 | $0 |
| Chicago Biosolutions, Inc. | Chicago, IL | 1 | $3.3 million | 0 | $0 |
| Rensselaer Polytechnic Institute | Troy, NY | 1 | $3.3 million | 0 | $0 |
| Brown University | Providence, RI | 2 | $3.2 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 5 | $3.2 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 547 | $442,861,006 | 0 | $0 |
| 2024 | 597 | $470,760,771 | 0 | $0 |
| 2023 | 444 | $430,271,867 | 0 | $0 |
| 2022 | 288 | $347,740,132 | 0 | $0 |
| 2021 | 190 | $335,837,726 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 9 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-24-182 | NIH | May 8, 2027 | Not listed | Notice number printed on 4 awards here | |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 2 awards here | |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 450 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 450 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 450 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 450 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 450 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 450 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 450 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 450 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 450 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 450 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 450 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 450 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 450 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 450 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 450 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 450 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.